FACIT.com
4
48M
2
0.50
1
- Areas of investment
Summary
The fund was located in Europe if to be more exact in Sweden. The main department of described Corporate Investor is located in the Stockholm.
The usual cause for the fund is to invest in rounds with 6 partakers. Despite the FACIT.com, startups are often financed by Versant Ventures, TPG Biotech, Johnson & Johnson Development Corporation. The meaningful sponsors for the fund in investment in the same round are TPG Biotech, HealthCap, Genesys Capital. In the next rounds fund is usually obtained by Varian Medical Systems, TPG Biotech, Seroba Life Sciences.
Among the various public portfolio startups of the fund, we may underline Fusion Pharmaceuticals, Turnstone Biologics The fund has no exact preference in a number of founders of portfolio startups. Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund. For fund there is no match between the country of its foundation and the country of its the most frequent investments - Canada. Among the most popular fund investment industries, there are Pharmaceutical, Biotechnology.
The high activity for fund was in 2017. Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is constantly included in less than 2 deals per year.
Investments analytics
Analytics
- Total investments
- 4
- Lead investments
- 0
- Exits
- 1
- Follow on index
- 0.50
- Investments by industry
- Biotechnology (4)
- Medical (3)
- Biopharma (3)
- Pharmaceutical (3)
- Clinical Trials (3) Show 2 more
- Investments by region
-
- Canada (3)
- United States (1)
- Peak activity year
- 2017
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 6
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Turnstone Biologics | 02 Nov 2016 | Biotechnology, Therapeutics, Innovation Management | Early Stage Venture | 41M | United States, California, San Francisco |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.